Perth's Sir Charles Gairdner Hospital haematology department and Hollywood Private Hospital oncology service manage multiple myeloma patients from across Western Australia. Following Revlimid patent expiry, Lenalid 25mg provides Perth myeloma patients — including those in self-funded treatment or facing PBS eligibility delays — with dramatically more affordable access to this backbone IMiD therapy.
Western Australia's mining industry workforce — with its occupational health-focused culture — creates a patient population acutely aware of medication costs and quality. Generic Lenalid's WHO-GMP certification provides Perth patients and their haematologists with confidence in clinical equivalence, while its dramatically lower cost enables the sustained long-term maintenance therapy that produces the best myeloma outcomes.
Visit medshopy.com or WhatsApp +91 82650 41513 for Perth and WA supply.
What is CAR-T cell therapy for myeloma and how does it compare to Lenalidomide-based treatment?
Western Australia's mining industry workforce — with its occupational health-focused culture — creates a patient population acutely aware of medication costs and quality. Generic Lenalid's WHO-GMP certification provides Perth patients and their haematologists with confidence in clinical equivalence, while its dramatically lower cost enables the sustained long-term maintenance therapy that produces the best myeloma outcomes.
Visit medshopy.com or WhatsApp +91 82650 41513 for Perth and WA supply.
What is CAR-T cell therapy for myeloma and how does it compare to Lenalidomide-based treatment?CAR-T (Chimeric Antigen Receptor T-cell) therapy is a revolutionary approach where a patient's own T cells are extracted, genetically engineered to recognise myeloma cells through a specific antigen (BCMA or GPRC5D), and infused back to hunt and kill cancer cells. Approved CAR-T products for myeloma include Ciltacabtagene autoleucel (Carvykti) and Idecabtagene vicleucel (Abecma). CAR-T is currently used for relapsed/refractory myeloma in patients who have received multiple prior therapies — not as a first-line alternative to Lenalidomide-based approaches. It can produce remarkable deep remissions including complete responses in a meaningful proportion of heavily pre-treated patients. However, CAR-T is a one-time complex cellular therapy requiring specialist centres, significant hospitalisation, and is not yet available as a routine therapy in WA outside clinical trials. Lenalidomide-based maintenance remains the cornerstone of front-line and second-line management, with CAR-T reserved for later-line relapsed disease.
